Replies to post #3921 on Organovo Holdings, Inc. (ONVO)

[anarmyofme]

Lickin' my chops here! Looks very promising.


I want to give you an overview of the partner model opportunity for us here. The partner model then as I said is to partner with pharma companies directly. Here we have an opportunity to build assets over time. And I mentioned that we have to build the tissue to be used in the drug discovery analysis, that's what I am mentioning here. You see as liver cancer, lung kidney, these are all areas where we can build tissues and then leverage those into doing discovery deals. We believe there are a loyalty and milestones in the range of 3% to 7% royalty and 10 million to 30 million milestone payouts. Those are the opportunities we can get to, and that's validated by the history of companies like Abgenix, Medarex, companies that had major exits in this space based on in their case monoclonal antibody technologies doing a very similar thing. - See more at: http://www.earningsimpact.com/Transcript/83967/ONVO/Organovo-Holdings-Inc---Organovo-Holdings,-Inc--At-RetailInvestorConferences-com/Page/4#sthash.Ma6NQz1b.dpuf